Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30017854 | 0.86 | SSTR4 (0.59) | SSTR4 | |
| SCHEMBL25481602 | 0.86 | SSTR4 (0.59) | SSTR4 | |
| SCHEMBL17754963 | 0.85 | SSTR4 (0.60) | SSTR4 | |
| SCHEMBL23886270 | 0.85 | SSTR4 (0.65) | SSTR4 | |
| SCHEMBL16255874 | 0.79 | SSTR4 (0.68) | SSTR4 | |
| SCHEMBL19724818 | 0.79 | SSTR4 (0.68) | SSTR4 | |
| SCHEMBL31560766 | 0.78 | SSTR4 (0.54) | SSTR4 | |
| SCHEMBL17763216 | 0.76 | SSTR4 (0.63) | SSTR4 | |
| SCHEMBL17755072 | 0.76 | CHEK1 (0.41) | SSTR4LCK | |
| SCHEMBL22015963 | 0.76 | SSTR4 (0.54) | SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368625-A1 | PIPERAZINES | Grünenthal GmbH (DE) | 2025-12-04 | — | — | US | disclosed |
| CN-115380030-B | N-heteroarylalkyl-2- (heterocyclyl and heterocyclylmethyl) acetamide derivatives as SSTR4 agonists | 武田药品工业株式会社 | 2025-05-16 | — | — | CN | disclosed |
| US-20230150981-A1 | N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230150981-A1 | N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-18 | — | — | US | disclosed |
| EP-4126848-A1 | N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2023-02-08 | — | — | EP | disclosed |
| CN-115380030-A | N-heteroarylalkyl-2- (heterocyclyl and heterocyclylmethyl) acetamide derivatives as SSTR4 agonists | 武田药品工业株式会社 | 2022-11-22 | — | — | CN | disclosed |
| EP-3218372-B1 | MORPHOLINE AND 1,4-OXAZEPANE AMIDES AS SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2020-05-20 | — | — | EP | disclosed |
| US-10577336-B2 | Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (SSTR4) agonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-03-03 | — | — | US | disclosed |
| US-10183940-B2 | Aryl and heteroaryl-fused tetrahydro-1,4-oxazepine amides as somatostatin receptor subtype 4 (SSTR4) agonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-01-22 | — | — | US | disclosed |
| US-20170320838-A1 | MORPHOLINE AND 1,4-OXAZEPANE AMIDES AS SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-11-09 | — | — | US | disclosed |
| US-20170320838-A1 | MORPHOLINE AND 1,4-OXAZEPANE AMIDES AS SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-11-09 | — | — | US | disclosed |
| WO-2016075240-A1 | MORPHOLINE AND 1,4-OXAZEPANE AMIDES AS SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-19 | — | — | WO | disclosed |
| WO-2016075239-A1 | ARYL AND HETEROARYL-FUSED TETRAHYDRO-1,4-OXAZEPINE AMIDES AS SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320838-A1 | MORPHOLINE AND 1,4-OXAZEPANE AMIDES AS SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | SSTR4, SSTR1, SSTR3 | SSTR4 1/4885LCK 1784/4885 |
| US-10577336-B2 | Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (SSTR4) agonists | SSTR4, SSTR1, SSTR3 | SSTR4 1/4885LCK 1784/4885 |
| US-20230150981-A1 | N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS | SSTR4, SSTR3, SSTR5 | SSTR4 1/4885LCK 2446/4885 |
| US-10183940-B2 | Aryl and heteroaryl-fused tetrahydro-1,4-oxazepine amides as somatostatin receptor subtype 4 (SSTR4) agonists | SSTR4, SSTR3, SSTR5 | SSTR4 1/4885LCK 1033/4885 |
| US-20250368625-A1 | PIPERAZINES | SSTR4, SSTR5, SSTR2 | SSTR4 1/4885LCK 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.